The Cooper Companies, Inc. (COO) Down 4.7% — Time to Rebalance My Portfolio?
The Cooper Companies, Inc. (COO) endured a rough Wednesday session on the NASDAQ, sliding 4.71% and shedding $3.19 to close at $64.50. The move extends a painful longer-term downtrend—COO now sits roughly 28.2% below its 52-week high of $89.83, a level last reached on December 5, 2025. That kind of distance from a prior peak carries its own signal, and today's session did nothing to close the gap.
Volume came in at approximately 2.76 million shares, running modestly above the 90-day average of about 2.53 million. The uptick in turnover against a declining price suggests selling pressure was the dominant force driving activity rather than any rotation or repositioning in the stock's favor.
Why The Cooper Companies, Inc. Price is Moving Lower
The clearest catalyst for today's decline was investor selling ahead of the company's fiscal Q3 earnings release, scheduled after market close on September 9. Pre-earnings repositioning of this kind—where shareholders reduce exposure before a potentially market-moving event—reflects genuine uncertainty about what the numbers will show, and that anxiety was visible in COO's 4.83% intraday drop. When investors are willing to exit at current levels rather than hold through a report, it signals that confidence in a positive earnings surprise is limited.
That hesitation is understandable given where the stock stands fundamentally. Revenue growth of 7.90% is modest for a company trading at a forward P/E of 57.87—a valuation that demands a considerably more aggressive growth trajectory to justify. Profit margins at 5.57% leave little cushion if top-line momentum stalls or costs rise, and a return on equity of just 2.85% raises legitimate questions about how effectively the business is converting shareholder capital into earnings. Heading into a quarterly report with those metrics in the background, investors had reason to tread carefully rather than press their bets.
What is the The Cooper Companies, Inc. Rating - Should I Sell?
Weiss Ratings assigns COO a D rating. Current recommendation is Sell. That assessment reflects a combination of subpar operating metrics and a risk profile that does not justify the stock's current valuation, particularly as the business heads into a critical earnings test.
The sub-index breakdown tells a candid story. Revenue growth of 7.90% earns a Weak Growth Index—a pace that struggles to support a forward P/E of 57.87 in a sector where investors demand clear earnings visibility. The 5.57% profit margin and 2.85% ROE together underpin a Fair Efficiency Index, highlighting that Cooper's asset base and equity capital are not working hard enough for a medical device and services company competing against larger, better-capitalized peers. The Weak Total Return Index and Weak Volatility Index reinforce the concern—shareholders have not been rewarded for holding the stock, and the ride has been bumpy along the way.
The one bright spot in the index framework is the Excellent Solvency Index, which suggests the balance sheet carries manageable leverage and the company is not at immediate risk of financial distress. That provides some structural floor, but solvency alone is a low bar—it tells investors the company can survive, not that it can outperform.
Within the Health Care sector, Cooper is on par with Centene Corporation (CNC, D) and below Boston Scientific Corporation (BSX, D+), Becton, Dickinson and Company (BDX, D+), and Medline Inc. (MDLN, D+). Only Guardant Health, Inc. (GH, D-) carries a weaker rating in this peer group. That relative positioning—clustered near the bottom of an already cautious peer set—reinforces why Weiss maintains a Sell stance on the stock.
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) is a Health Care company built around two core business segments that serve distinct but complementary medical markets. CooperVision, its largest division, is a global manufacturer of soft contact lenses—including daily, monthly, and specialty lenses—with a particular emphasis on myopia management products that address growing global demand for corrective solutions in younger patient populations. That segment competes directly with larger optical players and has historically leveraged product innovation and a broad international distribution network as key differentiators.
The company's second segment, CooperSurgical, focuses on women's health, fertility, and medical devices used in obstetrics and gynecology. Its portfolio spans intrauterine devices, fertility-related consumables and capital equipment, and surgical tools used across hospital and office-based settings. The fertility franchise in particular has become a meaningful growth driver as assisted reproductive technology adoption expands globally, lending the business some exposure to a structurally growing end market.
Across both divisions, Cooper benefits from a recurring-revenue model—contact lenses require regular replacement, and fertility clinics consume consumables on an ongoing basis—which provides a degree of revenue visibility that pure capital equipment businesses lack. The company also maintains a notable intellectual property position in specialty lens design and fertility diagnostics, supporting pricing discipline and long product life cycles. Its international footprint, spanning major markets in Europe, Asia-Pacific, and the Americas, adds geographic diversification but also introduces currency and regulatory complexity that investors must weigh.
Investor Outlook
The Cooper Companies, Inc. (COO) carries a Weiss Rating of D (Sell), and the fiscal Q3 earnings report due after market close on September 9 will be the immediate focus—any guidance commentary on contact lens demand trends or fertility volumes could materially shift sentiment in either direction. With the stock already 28.2% below its 52-week high and trading at a valuation that leaves little room for disappointment, investors should monitor whether management can offer a credible path to margin expansion and accelerating growth. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--